|Articles|August 6, 2014
Risk and Innovation in Biopharma: A CEO’s Perspective
Author(s)Guest Blogger
In this Applied Clinical Trials article, Kadmon CEO Dr. Sam Waksal talks about the importance of imagination for innovation, current business risks in biopharma, and applying understanding to the concept of Big Data.
Advertisement
In this Applied Clinical Trials article, Kadmon CEO Dr. Sam Waksal talks about the importance of imagination for innovation, current business risks in biopharma, and applying understanding to the concept of Big Data.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Why ‘Fully Staffed’ Field Teams Still Miss Revenue Targets—and How Pharma Can Fix It
2
Pharma M&A Roundup: Ipsen to Acquire Kartos Therapeutics, Zymeworks to Acquire Theravance Biopharma
3
The New Healthy Aging Imperative and What It Means for Pharma
4
EMA’s CHMP Recommends Eli Lilly’s Jaypirca for Approval
5